GlaxoSmithKline is to invest $20 million over five years to create an HIV research center and a company in partnership with the University of North Carolina at Chapel Hill.
Researchers from both UNC and GSK will work at the HIV Cure center, which will be located on the university’s Chapel Hill campus, and research will focus on curing HIV and Aids.
The two organizations will also jointly own and operate a company called Qura Therapeutics. Qura will reportedly retain rights to intellectual property developed from the research partnership.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.